Blood Cancer Diagnosis, Treatment & Cost
PACE Hospitals offers comprehensive
blood cancer treatment in Hyderabad, India, providing personalized care for patients diagnosed with different types of blood cancer, including leukemia, lymphoma, and multiple myeloma. Our multidisciplinary oncology team ensures accurate diagnosis through advanced blood tests, bone marrow examination, immunophenotyping, and molecular studies to identify the disease type and stage. Based on precise diagnosis, treatment plans are tailored to improve outcomes, optimize recovery, and enhance the overall success rate while ensuring patient safety and long-term care.
Book an Appointment for Blood Cancer Treatment
Blood Cancer Treatment Appointment
Why Choose PACE Hospitals for Blood Cancer Treatment?
Advanced Diagnostic Facilities: Complete Blood Tests, Peripheral Smear, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetics & Molecular Testing
Expert Oncologists in Hyderabad for Comprehensive Blood Cancer Care
Personalized Blood Cancer Treatment with Chemotherapy, Targeted Therapy & Immunotherapy
Affordable Blood Cancer Treatment with Insurance & Cashless Options
Blood Cancer Diagnosis
Blood cancer diagnosis is mainly based on a comprehensive clinical evaluation, including detailed medical history and physical examination, to identify symptoms and signs suggestive of a hematologic malignancy. These initial findings help guide the selection of appropriate diagnostic investigations.
The steps involved in diagnosing blood cancer are outlined below:
Medical history
Doctors take a thorough medical history by asking patients about symptoms (fatigue, fever, night sweats, bruising, infections, bone pain, swelling), past illnesses, treatments, family history, risks, and lifestyle impacts to guide blood cancer diagnosis. They include the following:
- Can you describe your main symptoms—fatigue, weakness, or pallor?
- Have you had fever, night sweats, or unexplained weight loss?
- Do you experience bone or joint pain?
- Have you noticed easy bruising, bleeding, or frequent infections?
- Do you have any past medical conditions, such as anemia, blood disorders, or a past history of cancer?
- What medications, supplements, or prior treatments (like chemotherapy or immunosuppressants) have you taken?
- Do you have any drug or food allergies?
- Does anyone in your family have blood disorders, cancers, or genetic conditions?
- Do you smoke, drink alcohol, use recreational drugs, or have occupational exposures to chemicals, radiation, or toxins?
- Have you noticed swelling in your neck, armpits, groin, or abdominal pain/early fullness?
- Have you had previous investigations such as blood tests, bone marrow biopsy, or imaging studies, and what were the results?
- How have your symptoms affected your daily life, work, or school, and do you have support from family or friends?
Physical examination
A comprehensive physical examination checks for pallor, petechiae/purpura, lymphadenopathy, hepatosplenomegaly, gingival hypertrophy, bone tenderness, jaundice, and special signs to guide blood cancer diagnosis.
- The patient may appear pale, fatigued, or cachectic (severe physical wasting and weakness). Jaundice or cyanosis may be present in cases of hemolysis or severe anemia. Vital signs require careful assessment; fever may indicate infection, tachycardia can result from anemia, hypotension may suggest bleeding or sepsis, and tachypnea may be seen in anemia.
- The skin may show petechiae, purpura, ecchymoses, or spontaneous bleeding. Any rashes suggesting leukemia cutis or paraneoplastic phenomena (symptoms or conditions caused by cancer indirectly) may be present. Lymph nodes in the cervical, axillary, and inguinal regions are assessed for size, consistency, tenderness, and mobility, as generalized lymphadenopathy may indicate lymphoma or leukemic infiltration.
- Conjunctival pallor and oral mucosa are examined for bleeding, ulcers, or gingival hypertrophy, which is common in acute myeloid leukemia. Tonsillar enlargement may indicate lymphoma. The abdomen needs to be examined for hepatomegaly, splenomegaly, masses, tenderness, or early satiety, which may suggest lymphomatous involvement.
- Musculoskeletal examination includes assessment of bone tenderness, especially in long bones and the spine, as well as joint swelling or pain. Cardiovascular assessment needs to assess heart rate, rhythm, murmurs, and signs of bleeding such as bruising or mucosal hemorrhages.
- Respiratory assessment looks for signs of infection, pleural effusion, or airway compromise due to lymphadenopathy. Neurological evaluation includes assessing fatigue, confusion, headache, cranial nerve deficits, or neuropathy. Extremities need to be inspected for edema, cyanosis, deep vein thrombosis (DVT), and nail changes like koilonychia.
- Finally, special signs such as gingival hypertrophy (overgrowth of the gums), “blueberry muffin” lesions in neonatal leukemia, or testicular enlargement in relapse of acute lymphoblastic leukemia are noted.
Blood Cancer Tests
Based on the above information, a haematologist or oncologist advises the diagnostic tests to detect blood cancer. The following are the tests that might be recommended to diagnose blood cancer:
- Laboratory Tests
- Complete Blood Count (CBC)
- Peripheral Blood Smear
- Biochemical and Metabolic Tests
- Comprehensive Metabolic Panel
- Calcium and Creatinine
- Lactate Dehydrogenase (LDH) & Uric Acid
- Coagulation Profile
- Plasma Cell / Myeloma-Specific Tests (if suspected)
- Serum Protein Electrophoresis (SPEP) + Immunofixation
- Serum Free Light Chain Assay (FLC)
- 24-hour Urine Protein Electrophoresis (UPEP) + Immunofixation
- Bone Marrow Examination
- Bone Marrow Aspiration
- Bone Marrow Trephine (Core) Biopsy
- Additional Bone Marrow Studies:
- Immunophenotyping / Flow Cytometry
- Cytogenetic Tests:
- Conventional karyotyping
- Fluorescence in situ hybridisation (FISH)
- Molecular Tests:
- PCR-based assays (detect recurrent fusions/mutations)
- Next-generation sequencing panels for classification, risk stratification, and actionable mutations
- Tissue Biopsy (for suspected lymphoma)
- Excisional Lymph Node Biopsy
- Histopathology & Ancillary Studies
- Imaging Studies
- PET/CT – Positron Emission Tomography / Computed Tomography
- CT – Computed Tomography
- MRI – Magnetic Resonance Imaging
- Supportive/Optional Imaging
- USG (Ultrasound)
- X-rays
- Additional Tests (Selected Cases)
- Lumbar Puncture / CSF Evaluation
Laboratory Tests
- Complete Blood Count (CBC): It helps to measure the number and types of blood cells, including red cells (RBC), white cells (WBC), and platelets. Abnormal counts may suggest leukemia, lymphoma, or other blood cancers, and it also helps monitor disease progression and response to therapy.
- Peripheral Blood Smear: A peripheral smear examines blood cells under a microscope to detect abnormal shapes, sizes, or immature cells (blasts). It can identify features such as Auer rods (needle-like inclusions in the cytoplasm of myeloblasts) in acute myeloid leukemia or abnormal lymphocytes in chronic lymphocytic leukemia, and helps in early detection and classification.
Biochemical and Metabolic Tests
- Comprehensive Metabolic Panel (CMP): It checks liver and kidney function, electrolyte levels, and overall metabolism. It can also identify organ involvement or complications from cancer, such as liver damage or tumor lysis syndrome.
- Calcium and Creatinine: High calcium levels can show bone problems, as in multiple myeloma, while creatinine shows how well the kidneys are working, which cancer or its byproducts can affect. Monitoring these levels helps prevent kidney damage and manage related complications.
- Lactate Dehydrogenase (LDH) & Uric Acid: Elevated LDH indicates high cell turnover or tissue damage, while high uric acid may result from rapid cancer cell breakdown. Both are markers of disease activity and can indicate aggressive or advanced blood cancers.
- Coagulation Profile: It evaluates blood clotting function, as some blood cancers can cause abnormal bleeding or thrombosis. It also guides the safe performance of procedures like bone marrow biopsy.
- Liver Function Tests (LFTs): In blood cancers, abnormal cancer cells may involve the liver or affect it indirectly, leading to raised liver enzymes or bilirubin levels. Abnormal LFTs can suggest liver involvement, treatment-related liver stress, or complications.
Plasma Cell / Myeloma-Specific Tests (if suspected)
- Serum Protein Electrophoresis (SPEP) + Immunofixation: This identifies abnormal monoclonal proteins (M-proteins) produced by malignant plasma cells, while immunofixation confirms the specific type (IgG, IgA, or light chains). These tests are important for diagnosing and monitoring multiple myeloma.
- Serum Free Light Chain Assay (FLC): FLC measures free kappa and lambda light chains in the blood. Abnormal ratios indicate plasma cell disorders, including non-secretory or light chain-only myeloma, and help track treatment response.
- 24-hour Urine Protein Electrophoresis (UPEP) + Immunofixation: It detects Bence-Jones proteins in urine, a hallmark of multiple myeloma, and immunofixation identifies the specific light-chain type. This test also helps assess kidney involvement and disease severity.
Bone Marrow Examination
- Bone Marrow Aspiration: Aspiration extracts liquid marrow for examination of cellular composition. It detects leukemia, lymphoma infiltration, or abnormal plasma cells, and allows cytochemical and molecular studies for precise diagnosis.
- Bone Marrow Trephine (Core) Biopsy: The core biopsy removes solid marrow to evaluate marrow architecture, cellularity, fibrosis, and tumor infiltration. It provides information that aspiration alone may miss and helps confirm the extent of the disease.
Additional Bone Marrow Studies
- Immunophenotyping / Flow Cytometry: This helps to identify specific cell surface markers to classify leukemia or lymphoma and distinguish malignant from normal cells. This is essential for diagnosis, prognosis, and targeted therapy selection.
Cytogenetic Tests
- Conventional Karyotyping: Karyotyping examines chromosomes for structural abnormalities or translocations linked to leukemia or lymphoma. It can also detect numerical changes, such as trisomy or deletions, that affect prognosis and treatment decisions.
- Fluorescence in situ Hybridisation (FISH): FISH detects specific genetic abnormalities with higher sensitivity than karyotyping. It identifies high-risk mutations or chromosomal changes, guiding treatment options.
Molecular Tests
- Polymerase Chain Reaction based Assays: It detects specific genetic fusions or mutations that are recurrent in leukemias or lymphomas. It is highly sensitive, helpful for diagnosis, monitoring minimal residual disease, and detecting early relapse.
- Next-Generation Sequencing (NGS) Panels: NGS analyses multiple genes simultaneously to classify blood cancers, identify prognostic markers, and detect actionable mutations. It helps guide targeted therapy and risk-adapted treatment strategies.
Tissue Biopsy (for suspected lymphoma)
- Excisional Lymph Node Biopsy: It involves the removal of an entire lymph node, which allows complete examination of the architecture and cellular composition. It is the gold standard for diagnosing lymphoma and differentiating between subtypes.
- Histopathology and Supportive Tests: Microscopic analysis of tissue, together with immunohistochemistry, flow cytometry, or molecular testing, is used to determine the lymphoma type and grade and to guide treatment and predict outcomes.
Imaging Studies
- Positron Emission Tomography / Computed Tomography (PET/CT): It detects areas of metabolically active cancer cells and evaluates disease extent in lymphoma and some leukemias. It is useful for staging, treatment response assessment, and relapse detection.
- Computed Tomography (CT scan): It provides detailed cross-sectional images of organs, lymph nodes, and bone marrow involvement. It helps identify tumor masses, organ enlargement, and structural complications of blood cancers.
- Magnetic Resonance Imaging (MRI): It provides high-resolution images of soft tissues, the spinal cord, and the brain. It is useful in leukemia or lymphoma when central nervous system (CNS) involvement or bone marrow lesions are suspected.
Supportive/Optional Imaging
- Ultrasound (USG): It assesses superficial lymph nodes, spleen, liver, or abdominal masses. It is non-invasive, radiation-free, and helpful for guiding biopsy or follow-up in blood cancers.
- X-rays: They detect bone lesions, fractures, or chest involvement in multiple myeloma and other leukemias. They are basic, widely available, and effective for preliminary evaluations.
Additional Tests (Selected Cases)
- Lumbar Puncture / CSF Evaluation: It collects cerebrospinal fluid (CSF) to detect leukemic or lymphomatous cells in the CNS. It is important for diagnosing CNS involvement, guiding intrathecal therapy, and monitoring response.
✅Blood Cancer Differential Diagnosis
Blood cancers and their types often present with non-specific clinical manifestations, which may overlap with benign conditions and other cancers. Accurate diagnosis relies on clinical history, complete blood count (CBC), peripheral smear, flow cytometry, and bone marrow examination.
Below is a detailed overview of important differential diagnoses of blood cancer:
- Infections: Viral (EBV, CMV) or bacterial infections can cause abnormal blood counts, lymphocytosis, or cytopenias that mimic leukaemia. Signs like fever and lymphadenopathy resolve with infection treatment, and PCR/serology confirms the etiology.
- Vitamin/ micronutrient deficiencies: Vitamin B12 or folate deficiencies can cause macrocytic anemia and hypersegmented neutrophils, which may look like leukemia or myelodysplasia. Unlike cancer, these changes usually improve once the deficiency is corrected.
- Myelodysplastic Syndromes (MDS): Myelodysplastic syndromes (MDS) cause low blood counts and abnormal-looking marrow cells, but usually have less than 20% blasts, which helps distinguish them from acute leukemia. Genetic tests, such as checking for del(5q), and flow cytometry can confirm the diagnosis.
- Aplastic Anemia: It is marked by low counts of all blood cells and a bone marrow that is unusually empty, without abnormal blasts. Patients usually improve with immunosuppressive treatment, which helps distinguish it from leukemia, where the marrow is overfilled with malignant cells.
- Non-Hodgkin Lymphoma (NHL) with leukemic spillover: Aggressive NHL subtypes can present with circulating malignant cells resembling leukemia. Immunophenotyping and lymph node biopsy reveal nodal architecture disruption, unlike leukemia which is marrow-centered.
- Plasma Cell Disorders: Multiple myeloma and plasma cell leukemia may present with circulating plasma cells and bone marrow infiltration. Immunophenotyping, such as markers such as CD138 and light-chain restriction, helps in distinguishing these disorders from other leukemias.
- Therapy-Related Leukemias: Prior chemotherapy or toxin exposure may result in temporary cytopenias or aberrant blasts. The timing of exposure and resolution after withdrawal aids in the differentiation of de novo leukemia.
- Chronic Leukemias (CML, CLL): Chronic leukemias can show high white blood cell counts and an enlarged spleen. Identifying specific genetic or cell markers, such as BCR-ABL1 for CML or monoclonal B-cell markers for CLL, is important to make the correct diagnosis.
- Mixed Phenotype Acute Leukemia (MPAL): MPAL shows both myeloid and lymphoid markers on flow cytometry. This rare subtype has a poor prognosis and requires therapy targeting both lineages.
- Monoclonal B-Cell Lymphocytosis (MBL): It is a pre-leukemic condition characterized by a low number of clonal B-cells (<5 × 10⁹/L). Patients are usually monitored, as MBL can progress to chronic lymphocytic leukemia (CLL) over time.
✅Blood Cancer Goals of Treatment
Blood cancer treatment aims to control or eliminate malignant cells and prolong survival. It also seeks to restore normal blood function and maintain quality of life. The treatment goals include:
- To achieve lasting remission and long-term disease control by eliminating malignant blood cells and suppressing any remaining disease.
- To prolong survival and achieve a cure where possible, based on disease type, biology, and evidence from long-term clinical outcome studies.
- To prevent disease progression and relapse, through sustained control of residual disease and risk-adapted therapeutic strategies.
- To restore and sustain normal blood cell production, supporting healthy bone marrow function and balanced hematopoiesis.
- To maintain or enhance quality of life by reducing symptoms from the disease and side effects of treatment.
- To individualise therapy while minimising toxicity, using molecular, cytogenetic, and clinical risk stratification supported by precision oncology research.
Get a Medical Second Opinion for Blood Cancer Treatment
At PACE Hospitals, we are committed to providing our patients with the best possible care, and that includes offering second medical opinions with super specialists for treatment or surgery. We recommend everyone to get an expert advance medical second opinion, before taking decision for your treatment or surgery.
Blood Cancer Treatment
Blood cancer treatment aims to control or eliminate malignant blood cells, improve patient survival, and maintain quality of life. It is tailored to the type, stage, and progression of the disease, with close monitoring to manage complications and assess response. The following are the treatment options for blood cancer:
- Pharmacological Therapy
- Chemotherapy
- Targeted Therapy
- Immunomodulatory Drugs
- Antibody-based Agents
- Immunotherapy
- Checkpoint Inhibitors
- Cellular Therapies (CAR T-cells)
- Other Cell-based Therapies
- Bone Marrow Transplant
- Autologous Transplantation
- Allogeneic Transplantation
- Radiation Therapy
- External Beam Radiation
- Total Body Irradiation
- Supportive and Adjunctive Care
- Growth Factor Support
- Transfusion Support
- Infection Prevention & Nutritional Support
Pharmacological Therapy
- Chemotherapy: Chemotherapy uses cytotoxic drugs to kill rapidly dividing cancer cells in the blood and bone marrow. It is often given in cycles to maximize efficacy while allowing recovery of normal cells. Chemotherapy can be used alone or in combination with other therapies to achieve remission and reduce tumour burden. Close monitoring is necessary to manage side effects such as myelosuppression, nausea, and infections.
- Targeted Therapy: It blocks certain molecules or pathways that drive cancer cell growth, survival, or proliferation. By focusing on these molecular targets, it can reduce damage to normal cells compared to conventional chemotherapy. Targeted agents are selected based on genetic or molecular abnormalities identified in the patient's cancer. These therapies can be used alone or with other treatments to improve outcomes.
- Immunomodulatory Drugs (IMiDs): Immunomodulatory drugs enhance the immune system's ability to attack cancer cells while also directly inhibiting tumor growth. They are particularly effective in plasma cell disorders, such as multiple myeloma. These drugs work by affecting cytokine levels, blood vessel formation, and the tumor environment to slow disease progression. They can cause side effects such as blood clots and low blood cell counts, so careful monitoring is essential.
- Antibody-Based Agents: These are monoclonal antibodies designed to particularly recognize and bind to cancer cells. They can directly trigger tumor cell death or recruit the immune system to eliminate malignant cells. Some are linked to toxins or radioactive particles to improve their cancer-killing effects. They are mainly used in lymphomas, leukemias, and plasma cell disorders, offering high specificity and decreased systemic toxicity.
Immunotherapy
- Checkpoint Inhibitors: Checkpoint inhibitors block inhibitory signals that prevent immune cells from attacking cancer. By "releasing the brakes" on the immune system, they enhance T-cell-mediated destruction of malignant cells. They are increasingly used in lymphomas and selected leukemias. Immune-related adverse events, such as organ inflammation, require careful monitoring.
- Cellular Therapies (CAR-T cell therapy): CAR T-cell therapy involves engineering a patient's T cells to recognise and kill cancer cells. It has shown remarkable success in certain relapsed or refractory leukemias and lymphomas. Treatment can lead to cytokine release syndrome or neurotoxicity, necessitating specialized care. CAR T therapy is highly personalized and represents a significant advancement in immunotherapy.
- Other Cell-based Therapies: These include therapies using natural killer (NK) cells, dendritic cells, or tumor-infiltrating lymphocytes. They aim to enhance or redirect the immune system against malignant cells. These approaches are often investigational but show promise in improving outcomes and reducing relapse.
Bone Marrow Transplant
- Autologous Transplantation: Autologous transplantation uses healthy blood-forming cells collected from the patient and reinfused after high-dose chemotherapy. This approach allows intensive treatment while helping the bone marrow recover normal blood cell production. It is commonly used in multiple myeloma and selected lymphomas. While effective in reducing disease burden, it carries short-term risks such as infections and treatment-related toxicity.
- Allogeneic Transplantation: Allogeneic transplantation uses blood-forming cells obtained from a compatible donor. In addition to restoring bone marrow function, it provides an immune-mediated anti-cancer effect that can eliminate residual malignant cells. This method is utilized in high-risk leukemias and lymphomas, although it has complications such as graft-versus-host disease and transplant problems. This transplantation requires careful donor matching and long-term monitoring.
Radiation Therapy
- External Beam Radiation: External beam radiation delivers high-energy rays to specific areas to kill cancer cells. It is used to alleviate bulky tumors, treat localized disease, or relieve symptoms like pain or compression. Precision techniques minimise damage to surrounding healthy tissues.
- Total Body Irradiation (TBI): Total body irradiation exposes the entire body to controlled doses of radiation, usually before bone marrow transplantation. It aids in the elimination of remaining malignant cells and suppresses the immune system, facilitating successful transplant acceptance.
Supportive and Adjunctive Care
- Growth Factor Support: Growth factors, such as granulocyte colony-stimulating factor (G-CSF), stimulate bone marrow to produce WBC, reducing infection risk during chemotherapy-induced neutropenia. They help patients tolerate intensive treatments and maintain therapy schedules.
- Transfusion Support: Red blood cell and platelet transfusions correct anemia and thrombocytopenia caused by disease or treatment. Regular monitoring ensures safe and effective replacement to prevent fatigue, bleeding, and other complications.
- Infection Prevention & Nutritional Support: Blood cancer patients are highly susceptible to infections and malnutrition due to the disease and therapy. Prophylactic antibiotics, vaccinations, dietary support, and patient education are critical to maintaining health, improving outcomes, and enhancing quality of life.
✅Blood Cancer Prognosis
Prognosis for blood cancers, encompassing leukemias, lymphomas, and multiple myeloma, varies significantly by blood cancer type, genetic profile, patient age, and treatment response. With advances in chemotherapy, targeted therapy, immunotherapy, and bone marrow transplantation, survival outcomes have improved significantly over the past decades.
Acute leukemias generally have a more aggressive course. Adults with acute myeloid leukemia have a 5-year survival rate of 25-40%, with better outcomes in younger patients, those with low-risk illness, or those who undergo transplantation. Acute lymphoblastic leukemia (ALL) has successful results in children, with long-term survival rates of 8 5-90%, although adult survival rates vary from 40-70%.
Chronic blood malignancies had better long-term prognosis. Chronic lymphocytic leukemia (CLL) frequently takes an indolent course, with 5-year survival rates over 85%, although Hodgkin lymphoma is one of the most treatable malignancies, with 5-year survival rates exceeding 85-90% using contemporary therapy.
Key favorable prognostic factors include younger age, good performance status, favorable genetic features, achievement of complete remission, and low risk of relapse. Also, adverse prognostic factors include older age (above 60 years), high-risk genetic abnormalities, treatment-resistant disease, early relapse, and comorbid medical conditions.
Blood Cancer Treatment Cost in Hyderabad, India
The cost of Blood Cancer treatment in Hyderabad generally ranges from ₹60,000 to ₹10,00,000 and above (approx. US $720 – US $12,050).
The exact cost of treatment varies depending on the type of blood cancer (leukemia, lymphoma, or multiple myeloma), stage of the disease, patient age, overall health, and the treatment approach advised. Factors such as the need for chemotherapy, targeted therapy, immunotherapy, or radiation therapy, duration of treatment, hospital stay, and supportive care requirements also influence the overall cost — including cashless treatment options, TPA corporate tie-ups, and assistance with medical insurance wherever applicable.
Cost Breakdown According to Type of Blood Cancer Treatment
- Chemotherapy for Blood Cancer – ₹60,000 – ₹4,00,000 (US $720 – US $4,820)
- Targeted Therapy / Oral Cancer Medicines – ₹1,20,000 – ₹6,00,000 (US $1,445 – US $7,230)
- Immunotherapy (Monoclonal Antibodies / CAR-T Supportive Care) – ₹2,50,000 – ₹10,00,000 (US $3,010 – US $12,050)
- Radiation Therapy (When required) – ₹1,00,000 – ₹3,50,000 (US $1,205 – US $4,210)
- Supportive Care & Long-Term Monitoring – ₹50,000 – ₹2,00,000 (US $600 – US $2,410)
Frequently Asked Questions (FAQs) on Blood Cancer Treatment
Can blood cancer be cured?
Some blood cancers can be cured, particularly when diagnosed early and treated appropriately with treatments like chemotherapy, bone marrow transplants, and immunotherapy, resulting in remission. Hodgkin lymphoma has a high cure rates around 85%. Survival outcomes in leukemia vary widely depending on the specific subtype, patient age, and risk profile, with many patients achieving long-term survival. Although not all blood cancers are curable, advances in treatment have significantly improved survival and quality of life.
Is blood cancer hereditary?
Blood cancer is not inherited. Certain gene changes or family history can slightly increase the risk. Most cases happen due to mutations during life, often from environmental factors. If several family members are affected, genetic counseling may be recommended, although lifestyle and environmental exposures usually have a greater impact.
Which Is the best Hospital for Blood Cancer Treatment in Hyderabad, India?
PACE Hospitals, Hyderabad, is a trusted centre for the diagnosis and management of blood cancers, offering comprehensive care for patients with leukemia, lymphoma, and multiple myeloma.
We have experienced medical oncologists, hematologists, radiation oncologists, transplant specialists, pathologists, and oncology nursing teams following evidence-based treatment protocols to provide personalised cancer care focused on disease control, symptom relief, and improved survival outcomes.
We are equipped with advanced diagnostic laboratories, chemotherapy day-care units, bone marrow evaluation services, modern imaging, transfusion support, and infection-controlled oncology wards, PACE Hospitals ensures safe, effective, and patient-centred blood cancer treatment — supported by cashless insurance facilities, TPA corporate tie-ups, and smooth documentation assistance.
How to prevent blood cancer?
No sure prevention exists, but decreasing risk involves avoiding benzene exposure, smoking, radiation, and certain chemicals, maintaining a healthy weight, and getting vaccinations, like hepatitis or HPV. A balanced diet, exercise, and limiting alcohol may help lower the overall risk of cancer. Regular check-ups catch issues early, as genetic predispositions can't be fully controlled.
What is the life expectancy of someone with blood cancer?
Life expectancy for blood cancer depends on the type, stage, and how well the treatment works. Many patients live five years or more, and Hodgkin lymphoma is often curable. About 65% of people with leukemia survive five years, while 70–85% of those with non-Hodgkin lymphoma do. New treatments, such as targeted therapies, can extend life even in advanced cases, highlighting the importance of personalized care.
What Is the cost of Blood Cancer Treatment at PACE Hospitals, Hyderabad?
At PACE Hospitals, Hyderabad, the cost of blood cancer treatment typically ranges from ₹55,000 to ₹16,50,000 and above (approx. US $660 – US $19,900), making it a cost-effective option for advanced hematology and oncology care compared to others. However, the final cost depends on:
- Type of blood cancer (leukemia, lymphoma, myeloma)
- Stage and aggressiveness of the disease
- Type and duration of treatment required
- Need for chemotherapy, immunotherapy, or transplant
- Frequency of hospital visits or admissions
- Specialist expertise and technology used
- Diagnostic tests (bone marrow biopsy, blood tests, imaging)
- Blood transfusions and supportive medications
For early-stage or chronic blood cancers, costs remain toward the lower end, while advanced or aggressive cancers requiring prolonged therapy or stem cell transplant fall toward the higher range.
After a detailed hematology-oncology evaluation, diagnostic work-up, and staging assessment, our specialists provide a personalised treatment plan and transparent cost estimate, aligned with disease type, treatment goals, and long-term care needs.
What is the last stage of blood cancer treatment?
In end-stage blood cancer, treatment aims at relieving symptoms rather than curing the disease. Low-dose chemotherapy, immunotherapy, or hospice care may be used to control pain, fatigue, and other issues. This approach is common after relapse or when the disease no longer responds to standard treatments, with the focus on comfort and quality of life.
What does the CBC blood test indicate about cancer?
A complete blood count (CBC) test acts as a primary screening tool that measures levels of red blood cells, white blood cells, platelets, haemoglobin, and hematocrit. Abnormal results, such as very high or low white blood cell counts, low red blood cells (anemia), or low platelets, can indicate blood cancers like leukemia, lymphoma, or myeloma. However, these changes are not specific to cancer and require further tests for confirmation, as they can also signal infections or other conditions.
How to detect blood cancer?
Blood cancers are diagnosed through a series of tests starting with a complete blood count (CBC) to check for abnormal cells. Further tests are blood smears, bone marrow biopsies, genetic tests to detect chromosomal alterations, and imaging studies like CT scans. Flow cytometry helps identify specific cancer cells, and procedures such as a lumbar puncture can check if the cancer has spread. Early signs like fatigue, easy bruising, or frequent infections require a visit to a doctor.
Is blood cancer contagious?
No, blood cancer is not contagious and cannot spread person-to-person through contact, air, or bodily fluids. It results from the uncontrolled growth of faulty blood-forming cells in the bone marrow, driven by internal genetic changes. Unlike viruses, no pathogen transmits it.
Is blood cancer 100% curable?
Not all blood cancers can be completely cured, but many people can live for a long time without the disease coming back. Early-stage Hodgkin lymphoma is easier to treat, with almost a 90% cure rate, while aggressive or relapsed non-Hodgkin lymphoma and myeloma are more difficult to treat. Detecting the disease early and using tailored treatments, such as immunotherapy, greatly improve the chances of success.
Is chemo used for blood cancer?
Yes, Chemotherapy is a main treatment for most blood cancers, and it works by attacking rapidly dividing cancer cells in the blood and bone marrow. It is often used alongside radiation, immunotherapy, or transplants for leukemia, lymphoma, and myeloma. Side effects can happen, but they are usually managed with supportive care.
Can someone live a normal life with blood cancer?
After achieving remission, many patients are able to return to their normal routines, including work and daily activities, especially when treatment begins early. Chronic blood cancers, like indolent lymphoma, can usually be managed for many years with regular follow-up. Targeted therapies help minimize side effects and improve quality of life, although some ongoing care may still be needed.
What type of blood cancer is not curable?
No blood cancer is universally incurable, but aggressive or relapsed acute myeloid leukemia (AML), advanced myeloma, or certain high-grade lymphomas have poorer prognoses with lower cure rates. Indolent types can be managed long-term but rarely fully eradicated. Advances continue to improve even in challenging cases.
Is blood cancer a terminal disease?
Blood cancer is not always terminal; many types can be cured or managed long-term as chronic conditions. Although advanced stages can be serious, early treatment often leads to high remission rates. It is treatable and does not automatically mean death.
Can a person recover for blood cancer? and How much time it takes to recover?
Yes. Many people with blood cancer can go into complete remission, depending on the type of cancer and the treatment used. Treatments such as chemotherapy, bone marrow or stem cell transplants, and immunotherapy have greatly improved survival. For example, the overall 5‑year survival rate for leukemia has risen to around 70 percent, with even higher rates in children with certain types like acute lymphoblastic leukemia (over 90 percent in many cases). Other blood cancers, such as chronic lymphocytic leukemia have about an 85–90 percent 5‑year survival, and many forms of lymphoma also have high survival rates with modern treatment. Some patients, especially those with aggressive or advanced blood cancer, may continue to have health problems. However, many people, particularly those with types of blood cancer that respond well to treatment, can be cured or live for many years without the disease.
Are there any risk factors affecting blood cancer treatment?
Yes.Several risk factors can influence the effectiveness and tolerance of blood cancer treatment. Patient-related factors such as older age, poor physical condition, and existing chronic illnesses may limit the ability to tolerate intensive therapies and increase the likelihood of side effects. A weakened immune system also raises the risk of infections, which can delay or interrupt treatment.
Disease- and treatment-related factors are equally important. Genetic and molecular modifications in cancer cells can affect how well treatments work, while advanced disease stage, high tumor burden, and reduced bone marrow function can make therapy more challenging. In addition, prior chemotherapy or radiation exposure and the intensity of current treatment can lead to complications, treatment delays, or dose reductions, ultimately affecting treatment outcomes.
Can children get blood cancer?
Yes, children can get blood cancer, including leukemia and lymphoma, which are among the most frequent pediatric cancers globally. Acute lymphoblastic leukemia, in example, accounts for approximately 33% of malignancies in children aged 0-14, with peak incidence often occurring between ages 1-4 and tens of thousands of cases reported globally each year, with boys being more likely to get the disease. These conditions arise primarily from genetic mutations rather than lifestyle factors, with stable incidence trends observed over recent decades.
Can blood cancer affect fertility?
Yes. Blood cancer itself usually does not completely destroy fertility, but treatments such as chemotherapy, radiation, and bone marrow procedures can significantly reduce reproductive ability. These therapies can damage eggs in women and sperm in men, sometimes causing temporary or permanent infertility. Fertility preservation, like sperm, egg, embryo, or ovarian tissue freezing, should be discussed before starting treatment to improve chances of having children in the future.
What is wrist ligament injury treatment?
Wrist ligament injury treatment is guided by the severity of ligament damage and the stability of the wrist joint. Mild to moderate injuries (based on Grade level) are commonly managed with RICE techniques: resting, icing, compressing, and elevating methods, temporary immobilisation using a wrist splint or brace, along with activity modification to allow proper healing. Pain and swelling are addressed early, followed by a structured hand and wrist physiotherapy program to restore movement, strength, and function.
In cases where symptoms persist or joint instability is present, further evaluation may be required. Surgical intervention may be considered for complete ligament tears to restore wrist stability and prevent long-term complications such as chronic pain or reduced grip strength.
What is the level of pain during ligament injury?
Pain levels during a ligament injury can vary widely. Mild injuries may cause manageable discomfort, while complete tears for grade 3 ligament injury often result in significant pain and rapid swelling in the affected area. Pain intensity may decrease over time, but can persist with movement if the injury is not take care or properly treated.
